On Jun. 4, 2020, vaccine manufacturers MSD, GSK, Innovax, Serum Institute of India and Walvax pledged to ramp up human papillomavirus (HPV) vaccine supply availability for Gavi-supported countries. This commitment is part of an ongoing UNICEF-led tender that aims to enable Gavi to dramatically increase its reach from 50 million girls, as initially planned, to 84 million girls during the next five-year period, leading to the prevention of an estimated 1.4 million future deaths from cervical cancer.